Fixed|Duration Targeted Therapy with Venetoclax plus ...

EHA 2019: Introduction of a new fixed-duration targeted therapy with ...

Venetoclax plus obinutuzumab was confirmed to be superior to chlorambucil plus obinutuzumab with regard to the primary endpoint of progression ...

Ibrutinib Plus Venetoclax Determined by MRD Improves Survival in ...

Duration of ibrutinib and venetoclax, as determined by the patient's minimal residual disease, improved survival in patients with treatment- ...

Fixed-Duration Ibrutinib plus Venetoclax Regimen Promising as First ...

The randomized phase 2 CAPTIVATE clinical trial showed that first-line therapy with ibrutinib (Imbruvica) and venetoclax (Venclexta) for a fixed duration ...

ESMO Clinical Practice Guideline interim update on new targeted ...

The median duration of treatment with ibrutinib–venetoclax was 27 cycles. A non-powered subgroup analysis of patients with mutated IGHV status ...

Long-Term Data Showcase the Clinical Utility of Fixed-Duration ...

Fixed-duration venetoclax plus obinutuzumab demonstrated prolonged remissions compared with chemoimmunotherapy in elderly patients with ...

The Economic Impact of Treatment Sequencing in Chronic ... - MDPI

Venetoclax + obinutuzumab (VO) is a fixed-duration treatment (12 months) which has the potential to reduce the cost burden of treating CLL. The aim of this ...

Personalized Ibrutinib-Plus-Venetoclax Therapy New Treatment ...

This combination treatment was then continued for up to 6 years. The duration of the ibrutinib-plus-venetoclax treatment depended on the MRD response of the ...

Fixed-duration therapy with venetoclax-obinutuzumab in frontline CLL

Kirsten Fischer of the University of Cologne, Cologne, Germany, discusses data on a new fixed-duration targeted therapy with venetoclax plus ...

Expert Perspectives on Fixed Duration Therapy with Venetoclax + ...

A panel of experts discuss the role of fixed duration therapy with venetoclax and obinutuzumab, outlining their general approach for patient ...

Venetoclax therapy and emerging resistance mechanisms in acute ...

Venetoclax was shown to potently and selectively target Bcl-2 and induce caspase-dependent apoptosis of acute lymphoblastic leukaemia (ALL) cell ...

Fixed-Duration Venetoclax Plus Rituximab Confers Benefit in ...

There was a 100% response rate in patients who experienced disease progression after fixed-duration VenR therapy who then received ibrutinib (10 ...

Typical Treatment of Acute Myeloid Leukemia (Except APL)

This is often called a 7 + 3 regimen, because it means getting cytarabine continuously for 7 days, along with short infusions of an ...

Venetoclax consolidation after fixed-duration ... - The Lancet

Fixed-duration 12 cycles of venetoclax plus obinutuzumab is established as first-line treatment for patients with chronic lymphocytic leukaemia. We aimed to ...

Response to CLL Therapies After Fixed-Duration Venetoclax

The MURANO trial was a phase 3 clinical trial that compared fixed-duration venetoclax plus rituximab with bendamustine plus rituximab in ...

Fixed-duration pirtobrutinib plus venetoclax, rituximab promising in ...

Patients received pirtobrutinib plus venetoclax for up to 24 cycles; each cycle was 28 days. In the pirtobrutinib plus venetoclax plus rituximab ...

Clinical Trials Using Venetoclax - NCI

It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. There is evidence that these newer experimental treatment ...

Should VenO Be Extended Beyond One Year in CLL?

Fixed-duration VenO, a first-line targeted therapy-immunotherapy combination, involves a one-year course of treatment, with cessation ...

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL

Results from the cohort investigating fixed-duration treatment with ibrutinib plus venetoclax are reported. Patients received 3 cycles of ...

Evaluating the long-term effectiveness of fixed-duration treatment ...

Targeted therapies are commonly used in the treatment of CLL and improve survival. Venetoclax is a targeted therapy that works by blocking the ...

Treatment Duration Benefits - VENCLEXTA® (venetoclax tablets)

With ﬁxed-duration VENCLEXTA regimens, give your patients the chance for: ; Calendar Time off Treatment. Set a target stop date ; No Ongoing Treatment Exposure.